Neuroscience R&D Technologies Conference

Registration

Welcome note from MarketsandMarkets Conferences

Opening Remarks from the Chairman

Keynote Presentation: Stimulating neurogenesis for treatment of neurodegenerative diseases

Georg Terstappen , Chief Scientific Officer, OxStem

Role of Human IPSCs in Neuroscience and Pain Research

Deciphering the Identity of DIPG Cells to Develop Targeted Therapy Utilizing Genetically Engineered hNSCs

Yang (Ted) Teng, Director, Laboratory of SCI, Stem Cell & Neurofacilitation Research, Harvard University

How can we achieve better translation from in vitro to the clinic in neuroscience?

Paul Karila, CSO, Cellectricon

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

A Human iPSC-based Technology Platform for Amyotrophic Lateral Sclerosis Neuroinflammation Drug Discovery

Steven Biesmans , Senior Scientist, UCB

AI-driven phenotypic drug discovery delivers first-in-class, clinically effective neuropsychiatric treatments

Emer Leahy , CEO , Psychogenics

Introduction to Axols capabilities and how they can support your research

Nicholas Clare, Head, Customer Solutions, Axol Bioscience

Cellular models of Parkinson’s disease using toxins involve different dopaminergic neuron death processes: impact on drug screening

Noelle Callizot, Co-Founder, CSO, Neuro-Sys

Lunch and Poster Presentation | One-to-One Networking Meetings

Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling

Silvia Cainarca, Principal Investigator, Project Leader, IMI2 project -NGN-PET, Italy

Degenerative synaptopathies – progress and challenges

Frank Hirth , Group Leader Neural Circuits and , Behaviour King’s College London, UK

Optimizing next-generation drug development: RNA medicine meets systems biology

Winston Hide , C0-Director Non-Coding RNA Core, Harvard University

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

Preclinical development of new therapeutics: Opportunities and challenges.

Arshad Majid , Professor of Cerebrovascular Neurology, Director, Comprehensive Cerebrovascular Research unit (CCRU), University of Sheffield

From Translational Science in an Academic Setting to Commercial R&D in a Corporate Setting: Crossing the ‘Valley of Death’

David Taggart , Chief Operating Officer, Glycyx Therapeutics, USA

Panel: Challenges in the translation of pre-clinical to clinical research in CNS drug discovery

Closing Remarks from the Chairman

Drinks Reception & Networking

Registration

Welcome note from MnM Conferences

Opening Remarks from the Chairman

Frank Hirth , Group Leader Neural Circuits and , Behaviour King’s College London, UK

Keynote Presentation: Cell-type specific profiling of human brain for novel therapeutic development

Xiao Xu, Co-Founder, Cerevance, UK

Biomarkers and CNS Models

Strategies to enhance memory in old age and dementia

Karl Peter Giese, Professor, Neurobiology of Mental Health, King’s College London

TMS electro-diagnostic markers as a clinical readout for testing novel CNS therapeutics

Isabella Premoli, Research Lead, The Science Behind

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Why is Pharma so scared of psychiatric drug discovery is the fear justified?

Mark Tricklebank, Wellcome Trust Research Fellow, Neuroimaging, King’s College London, UK

A new functional in vitro assay for screening of antipsychotics

Olaf Schroder, CEO, Neuroproof, Germany

Neuromodulation and Deep Brain Stimulation

Neuroengineering solutions for brain repair

Michela Chiappalone , Associate Professor, University of Genova

Lunch and Poster Presentation | One-to-One Networking Meetings

Brain informatics – a gateway to cutting-edge brain research

Mufti Mahmud, Senior Lecturer, Computing & Technology, Nottingham Trent University,

Closing remarks from the Chairman

Afternoon Refreshments and End of Conference